There seems to be some extreme discomfort on this latest PR and the announcement/time frame of the binding version of the Bintai/Malaysia deal. Yes, it took weeks to get from the non-binding MOU to the latest PR. But it seems to me that some of us have been overlooking, or at least underestimating the value of, some pretty major items that developed in this latest announcement. Here are my observations:
1) The latest announcement is binding. This is essentially a deal that both parties want to do, and there is a certain level of commitment that was not there as of the August announcement.
2) Bintai negotiated expanded geographical rights since the MOU. They have first right to Australia/NZ (30MM people) and "the global HALAL markets, particularly in SE Asia". This could mean the Islamic countries in SE Asia or perhaps just the Islamic population of these countries. The Islamic population of SE Asia is shown as 240MM (https://en.wikipedia.org/wiki/Islam_by_country). The population of these countries is much higher. If this includes S Asia (Pakistan, etc.) and the Middle East, this becomes a huge number.
3) The MOU listed the fees as $3/vaccine. The new binding agreement states $3 for Malaysian gov't-paid vaccines and $4.50 for all private sector vaccines. I presume the Malaysian gov't wouldn't be administering vaccines in other countries, so we appear to have gotten a 50% increase on all of the other potential regions Bintai could get involved in (or more if someone else shows interest as we get further down the road).
4) They engaged a CRO... here is a concise definition that I found for a CRO's role:
"The main role of the CRO is to plan, coordinate, execute, and supervise the processes involved in the development of a clinical trial, being a central contact point between the sponsor and other trial actors (e.g. ethics committees, regulatory agencies, vendors, and hospitals).
CROs are key players in clinical research, since they have the knowledge and the capabilities needed for the proper development of a clinical study. They help sponsors by reducing their workload, while ensuring trial quality and compliance with national and international standards."
(https://www.sofpromed.com/what-is-a-cro/)
So they are preparing for a proper trial that will meet the Malaysian and presumably international requirements that will be needed to get approval across these regions.
I would also expect that this Malaysian CRO would have expertise in any aspects of medical development that might pertain to these target Islamic populations, helping to avoid/mitigate any cultural barriers that could arise.
This appears to be a significant improvement over the MOU, IMO.
Hopefully we will see some final ink on this deal this week, and we can start the clock on the $2.5MM payment and NGIO/Bintai can get the wheels turning on the peptides and setting up clinical trials.
Until then, we are (again, IMO) a significant step closer to the Malaysian+ deal, other countries may be taking notice that this could be a legit opportunity, the NGIO S1s are being reviewed, and Generex is still in business.
Have a great Sunday, everybody!
1) The latest announcement is binding. This is essentially a deal that both parties want to do, and there is a certain level of commitment that was not there as of the August announcement.
2) Bintai negotiated expanded geographical rights since the MOU. They have first right to Australia/NZ (30MM people) and "the global HALAL markets, particularly in SE Asia". This could mean the Islamic countries in SE Asia or perhaps just the Islamic population of these countries. The Islamic population of SE Asia is shown as 240MM (https://en.wikipedia.org/wiki/Islam_by_country). The population of these countries is much higher. If this includes S Asia (Pakistan, etc.) and the Middle East, this becomes a huge number.
3) The MOU listed the fees as $3/vaccine. The new binding agreement states $3 for Malaysian gov't-paid vaccines and $4.50 for all private sector vaccines. I presume the Malaysian gov't wouldn't be administering vaccines in other countries, so we appear to have gotten a 50% increase on all of the other potential regions Bintai could get involved in (or more if someone else shows interest as we get further down the road).
4) They engaged a CRO... here is a concise definition that I found for a CRO's role:
"The main role of the CRO is to plan, coordinate, execute, and supervise the processes involved in the development of a clinical trial, being a central contact point between the sponsor and other trial actors (e.g. ethics committees, regulatory agencies, vendors, and hospitals).
CROs are key players in clinical research, since they have the knowledge and the capabilities needed for the proper development of a clinical study. They help sponsors by reducing their workload, while ensuring trial quality and compliance with national and international standards."
(https://www.sofpromed.com/what-is-a-cro/)
So they are preparing for a proper trial that will meet the Malaysian and presumably international requirements that will be needed to get approval across these regions.
I would also expect that this Malaysian CRO would have expertise in any aspects of medical development that might pertain to these target Islamic populations, helping to avoid/mitigate any cultural barriers that could arise.
This appears to be a significant improvement over the MOU, IMO.
Hopefully we will see some final ink on this deal this week, and we can start the clock on the $2.5MM payment and NGIO/Bintai can get the wheels turning on the peptides and setting up clinical trials.
Until then, we are (again, IMO) a significant step closer to the Malaysian+ deal, other countries may be taking notice that this could be a legit opportunity, the NGIO S1s are being reviewed, and Generex is still in business.
Have a great Sunday, everybody!
8
